AICAR: The Original "Exercise in a Pill" — What the Evidence Actually Shows
AICAR is the prototype AMPK-activating exercise mimetic. The endurance hype rests entirely on mice; the only positive human data are from heart surgery.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-07-02A well-supported AMPK 'exercise-mimetic' whose endurance, fat-loss and longevity claims rest entirely on animal studies; the only human data are from unrelated hospital uses, and it is unapproved and WADA-prohibited.
Well-supported AMPK activation, the canonical energy-sensing 'exercise-mimetic' pathway.
Broad rodent endurance and metabolic data underpin the exercise-mimetic idea.
Human exposure on record is short-term hospital infusion for unrelated uses (cardiac surgery as acadesine, a small leukaemia trial); no human trial supports the marketed uses.
No human trial shows improved endurance, body composition or longevity; field researchers doubt the premise translates.
Short-term intravenous safety is partly characterised; a consistent signal is raised uric acid, with anaemia, low platelets, renal impairment and hypotension at higher exposure. Long-term safety for the marketed uses is unknown.
The exercise/fat-loss/longevity programme was never developed; grey-market use only.
Strong mechanism but no confirmatory human efficacy data.
Approved nowhere and WADA-prohibited (an anti-doping rule violation for tested athletes); grey-market material has no quality control.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
The prototype AMPK 'exercise-mimetic'. The endurance, fat-loss and longevity claims rest entirely on animal studies; the only positive human data are from a different use — cardiac surgery (as acadesine) — and a small leukaemia trial.
Safety snapshot
No long-term human safety data for the marketed uses; every human exposure on record was short-term hospital infusion. A consistent signal is raised uric acid (gout risk), with anaemia, low platelets, renal impairment and hypotension at higher intravenous exposure.
Regulatory & legality
Approved nowhere and WADA-prohibited (an anti-doping rule violation for tested athletes); grey-market material has no quality control.
Where claims can exceed the evidence
Not a single human trial shows it improves endurance, body composition or longevity; researchers in the field openly doubt the premise translates to people.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
AICAR (acadesine; 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside) is the compound that launched the phrase "exercise in a pill". The story is irresistible: a 2008 paper in Cell showed that four weeks of oral AICAR, with no training at all, raised treadmill endurance in sedentary mice by roughly 44% and switched on an exercise-like gene programme in muscle [1]. That single result is the engine behind almost everything written about AICAR in the performance and longevity space.
Here is the part the marketing leaves out. The endurance evidence is essentially all from animals. There are no human trials showing AICAR improves endurance, burns fat, or extends healthspan. Reviews of the field are blunt that AMPK has not been successfully drugged for metabolic disease in people [9][10]. Paradoxically, the strongest human data for this exact molecule come from a completely different world — heart surgery, where it was studied as "acadesine" — and from a small leukaemia trial. So the evidence is genuinely mixed: robust preclinical mechanism, real human safety and efficacy data in cardiac surgery, and a translational void where the performance claims should be. It is WADA-banned and approved nowhere.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
5-Amino-1MQ: The NNMT Inhibitor Behind the "Fat-Loss Peptide" Hype
5-Amino-1MQ is a small-molecule NNMT inhibitor with promising mouse and cell data for fat loss and muscle ageing — but zero human trials and no approval.
Epithalon (Epitalon): The Telomerase Peptide, Examined
A clear-eyed look at Epitalon, the pineal tetrapeptide pitched as a telomerase activator — what the evidence actually shows, and why it is weaker than the hype suggests.
MOTS-c: The Mitochondrial "Exercise Mimetic" Peptide — What the Evidence Actually Shows
A clear-eyed look at MOTS-c: strong mechanistic and rodent data for AMPK activation and insulin sensitivity, but human efficacy of the injected peptide is unproven.
NAD+ Boosting: What the Evidence Actually Shows
NAD+ precursors reliably raise blood NAD+ and are well tolerated, but human healthspan benefits stay unproven and IV NAD+ has essentially no outcome evidence.